The biopharma world is still processing the seismic news of Isomorphic Labs’ $2.1 billion Series B […]
Japan’s pharmaceutical pricing system is often seen as a local matter. It is discussed in terms […]
Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]
To all the healthcare innovation leaders, urban gerontologists, and care ecosystem designers in the world: if […]
Daiichi Sankyo is no longer best understood as a successful Japanese pharma company with a strong […]
Japan is one of the world’s most demanding healthcare markets. It is also one of the […]
Something quietly extraordinary has been happening in the heart of downtown Toronto. Within one of the […]